JPRN-UMIN000038211招募中未知
Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer after first-line gemcitabine plus nab-paclitaxel failure - Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with contraindication of FOLFIRINOX 2) Second primary malignancy 3) Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
尚未招募
2 期
Converison therapy of FOLFIRINOX in patients with unresectable locally advanced pancreatic cancer: A phase IInresectable locally advanced pancreatic cancerJPRN-UMIN000014039Yokohama City University50
招募中
2 期
eoadjuvant FOLFIRINOXPancreatic cancer, Neoadjuvant therapyPancreatic cancerJPRN-jRCT1041220027Yamashita Tatsuya50
已完成
2 期
Second-line chemotherapy FOLFIRINOX in unresectable cholangiocarcinomacholangiocarcinomaBile duct and gallbladder cancer10019815NL-OMON42542Academisch Medisch Centrum30
已完成
2 期
Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000015376Gifu University Hospital28
已完成
2 期
A phase II study of FOLFIRINOX in patients with advanced biliary tract cancerBiliary tract cancerJPRN-UMIN000020801Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo35